Article Text

Download PDFPDF

Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial
  1. Ying Zhao1,
  2. Wanyong Yang1,
  3. Zefeng Tan1,
  4. Wenmin Wang2,
  5. Weimin Xiao3,
  6. Jinsheng Zeng4,
  7. Anding Xu1
  1. 1 Department of Neurology and Stroke Center, The First Affiliated Hospital, Jinan University, Guangzhou, China
  2. 2 Department of Neurology, The First Affiliated Hospital, Kunming Medical College, Kunming, Yunnan, China
  3. 3 Department of Neurology, Dongguan People Hospital, Dongguan, Guangdong, China
  4. 4 Department of Neurology and Stroke Center, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
  1. Correspondence to Dr Anding Xu; tlil{at}jnu.edu.cn

Abstract

Aim The role of clopidogrel in treating patients with acute ischaemic stroke is unclear. We have conducted the clinical trial in order to evaluate the efficacy and safety of clopidogrel with a loading dose in treating patients with non-cardiogenic acute ischaemic stroke.

Method Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China) was a prospective, randomised, double-blind and placebo-controlled clinical trial in China. Patients with acute ischaemic stroke of non-cardiogenic origin within 48 hours of onset were enrolled and those received thrombolysis were excluded. Enrolled patients were divided into two treatment groups: loading dose and routine dose. The primary outcome was the incidence of stroke recurrence or progression within 7 days. Primary safety outcome was measured by life-threatening haemorrhage. An intent-to-treat analysis was used for the statistical analysis.

Results From March 2008 to March 2010, a total of 303 patients from 16 centres were recruited into this study; six were excluded because of lack of basic information. Since the enrolment was slow and the study drug expired in March 2010, this clinical trial was stopped earlier than planned. No significant baseline and demographic differences were seen between the two groups. There was no difference in primary outcome between the loading dosage group 16.1% (24/149) and control group 14.9% (22/148), respectively (p=0.782). The mortality and disability rate within 90 days in loading dose group (19.6%) was slightly lower than that in controlled group (23.4%), p=0.444. Loading dose group had two (1.3%) cases of fatal haemorrhage and control group had four (2.7%) within 90 days, p=0.674. No significant difference was detected in other adverse events between the groups.

Conclusion In our study stopped early due to slow enrolment, loading dose of clopidogrel does not reduce the risk of recurrent stroke. Future trials with sufficient number of patients enrolled are needed to re-examine this hypothesis.

  • Acute ischaemic stroke
  • non-cardiogenic stroke
  • clopidogrel
  • loading dose

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors All the listed authors have participated actively in the study, and have seen and approved the submitted manuscript. ZY was responsible for the statistical analysis of data and writing of paper. YW has contributed to conduct and reporting of the study. TZ, WW and XW were in charge of acquisition of data. ZJ and AX have contributed on the conception and design of the study, analysis and interpretation of data, and the modifications of the paper.

  • Funding This study was supported by the Science and Technology Program of Guangzhou (No. 201508020004), and received funding from the Medical Science and Technology Research of Guangdong Province (No. A2015461).

  • Competing interests None declared.

  • Patient consent Obtained

  • Ethics approval The First Affiliated Hospital of Sun Yat-Sen University.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No additional data are available.

  • Correction notice This article has been corrected since it published Online First. The author names have been corrected and an acknowledgement statement has been added.